<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01670734</url>
  </required_header>
  <id_info>
    <org_study_id>POP12671</org_study_id>
    <secondary_id>2012-002292-33</secondary_id>
    <secondary_id>U1111-1129-0248</secondary_id>
    <nct_id>NCT01670734</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Tolerability of Alirocumab SAR236553 (REGN727) in Patients With Hepatic Impairment and in Healthy Subjects</brief_title>
  <official_title>An Open-Label, Pharmacokinetic and Tolerability Study of SAR236553/REGN727 Given as a Single SC Dose in Subjects With Mild and Moderate Hepatic Impairment, and in Matched Subjects With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      Study the effect of mild or moderate hepatic impairment on the pharmacokinetics of alirocumab
      SAR236553 (REGN727).

      Secondary Objectives:

        -  Assess the safety and tolerability of alirocumab SAR236553 (REGN727) in patients with
           mild and moderate hepatic impairment and in matched subjects with normal hepatic
           function.

        -  Assess the pharmacodynamic profile of alirocumab SAR236553 (REGN727) in patients with
           hepatic impairment and in matched subjects with normal hepatic function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Total duration of the study per subject (excluding screening) is about 12 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Assessment of serum concentrations of alirocumab SAR236553 (REGN727)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter - terminal elimination half-life (t1/2z) [</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter - apparent total body clearance (CL/F)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter - Distribution volume at the steady-state (Vss/F)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter - time to maximum concentration (tmax)</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of PK parameter - Mean Residence Time (MRT [area])</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Change in LDL-C from baseline</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>Up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727) - mild hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection through subcutaneous (SC) administration in patients with mild hepatic function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727) - moderate hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection through subcutaneous (SC) administration in patients with moderate hepatic function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alirocumab SAR236553 (REGN727) - normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection through subcutaneous (SC) administration in patients with normal hepatic function</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alirocumab SAR236553 (REGN727)</intervention_name>
    <description>alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)
Pharmaceutical form:Solution for injection Route of administration: subcutaneous</description>
    <arm_group_label>alirocumab SAR236553 (REGN727) - mild hepatic function</arm_group_label>
    <arm_group_label>alirocumab SAR236553 (REGN727) - moderate hepatic function</arm_group_label>
    <arm_group_label>alirocumab SAR236553 (REGN727) - normal hepatic function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

          -  Male or female, between 18 to 75 years of age, inclusive.

          -  Patients with mild and moderate hepatic impairment based on Child-Pugh score and
             stable chronic liver disease.

          -  Healthy subjects with normal hepatic function.

        Exclusion criteria:

          -  Patients with acute hepatitis, hepatic encephalopathy grade 2, 3, and 4.

          -  Patients with history or presence of uncontrolled clinically relevant illness.

          -  Healthy subjects with history or presence of clinically relevant illness.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 250001</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 498001</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Moldova, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2012</study_first_submitted>
  <study_first_submitted_qc>August 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2012</study_first_posted>
  <last_update_submitted>June 27, 2013</last_update_submitted>
  <last_update_submitted_qc>June 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

